As a result of the significant disruption that is being caused by the COVID-19 pandemic we are very aware that many researchers will have difficulty in meeting the timelines associated with our peer review process during normal times. Please do let us know if you need additional time. Our systems will continue to remind you of the original timelines but we intend to be highly flexible at this time.
COVID-19 and impact on peer review
Featured Review: IgE autoantibodies and autoreactive T cells and their role in children and adults with atopic dermatitis
The pathophysiology of atopic dermatitis (AD) is highly complex and understanding of disease endotypes may improve disease management. Immunoglobulins E (IgE) against human skin epitopes (IgE autoantibodies) are thought to play a role in disease progression and prolongation.
In this review, researchers provide a summary of the current knowledge and gaps on IgE autoreactivity and self-reactive T cells in children and adults with AD based on a systematic search.
Featured Research: The association between airborne pollen monitoring and sensitization in the hot desert climate
The prevalence of asthma and allergic rhinitis is high and increasing in western countries. However, little is known about the prevalence rate of allergic disorders in the Middle East and Arab Gulf countries.
Al-Nesf and colleagues conducted the first study to monitor airborne pollen in the state of Qatar. The main pollen detected were Amaranthaceae and Poaceae. Pollen may represent a possible exacerbating factor in adult patients with allergic diseases such as asthma and allergic rhinitis.
Better recognition, diagnosis and management of non-IgE-mediated cow’s milk allergy in infancy: iMAP—an international interpretation of the MAP (Milk Allergy in Primary Care) guideline
Aims and scope
Clinical and Translational Allergy, one of several journals in the portfolio of the European Academy of Allergy and Clinical Immunology, provides a platform for the dissemination of allergy research and reviews, as well as EAACI position papers, task force reports and guidelines, amongst an international scientific audience.
Clinical and Translational Allergy accepts clinical and translational research in the following areas and other related topics: asthma, rhinitis, rhinosinusitis, drug hypersensitivity, allergic conjunctivitis, allergic skin diseases, atopic eczema, urticaria, angioedema, venom hypersensitivity, anaphylaxis, food allergy, immunotherapy, immune modulators and biologics, animal models of allergic disease, immune mechanisms, or any other topic related to allergic disease.
Open access publishing enables free access to all content ensuring a wide dissemination of articles; the electronic format and expert peer review allows for very rapid publication. Clinical and Translational Allergy is an international journal reaching out far beyond the borders of Europe, and invites clinicians and researchers from all countries of the world to contribute.
The EAACI Junior Members and Clinical and Translational Allergy are pleased to be working in conjunction to highlight must-read articles from recent publications. This collection aims to further the knowledge of medical residents and other young scientists.
Clinical & Tranlastional Allergy collaborates with EAACI Junior Members to produce interviews and podcasts featuring leading authors from recently published CTA articles.
We hope to shine a brighter light on our authors' world-leading research as well as provide EAACI Junior Members with the opportunity to meet and discuss the latest research with experts in the field.
The European Academy of Allergy and Clinical Immunology (EAACI) is an association of clinicians, researchers and allied health professionals, dedicated to improving the health of people affected by allergic diseases. With more than 11,000 members from 124 countries and over 50 National Allergy Societies, EAACI is the primary source of expertise in Europe for all aspects of allergy.
Allergic and immunologic diseases represent current crippling or life threatening conditions, and are a cause of worldwide concern. EAACI’s mission is to provide the most efficient platform for scientific communication and education in the field of allergy and immunology, ultimately striving to ease the lives of patients suffering from these diseases.
In pursuit of our mission, we seek to accomplish the following aims:
- Promoting basic and clinical research
- Collecting, assessing and disseminating scientific information
- Functioning as a scientific reference body for other scientific, health and political organisations
- Encouraging and providing training and continuous education
Promoting good patient care in this important area of medicine
For more information, please visit www.eaaci.org.
Review for CTA to CME credits
EAACI are now able to offer CME credits for qualifying reviewers of Clinical and Translational Allergy.
Please contact email@example.com if you would like to sign up.
Sign up to receive article alerts
Clinical and Translational Allergy is an online open access journal so we encourage you to sign up to receive free email alerts at a frequency of your choice and keep up to date with all of the latest articles.
Quote from the Editors
Dr Clive Grattan, St John’s Institute of Dermatology, London, UK
Dr Jean Bousquet, University of Montpellier, France
Clinical and Translational Allergy is a pioneering initiative to make high quality peer-reviewed research and reviews in allergy and related subjects available to clinicians, scientists and the public in an open-access format. Advances in allergy and immunology are being made in the clinic and in the laboratory at a rapid rate. CTA provides the platform for rapid dissemination of these findings to a wide audience to provide greatest impact and benefit to society.
EAACI focused meetings
Clinical and Translational Allergy is proud to be the official destination for the publication of abstracts from the EAACI focussed meetings. You can access these supplements here.
An official journal of EAACI
Annual Journal Metrics
48 days to first decision for reviewed manuscripts only
28 days to first decision for all manuscripts
100 days from submission to acceptance
19 days from acceptance to publication